The FDA Approved the First New Sickle Cell Drug in 20 Years…But It’s Not a Cure

Sy Mukherjee

<p>News that the Food and Drug Administration (FDA) <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm566084.htm" target="_blank" rel="noopener noreferrer">approved the first new drug</a> to treat sickle cell in nearly 20 years last Friday understandably drew cheers from patients and advocates who have stood by with bated breath for a breakthrough. But as laudable as the milestone may be, the treatment&#8217;s limited reach underscores just how hard it is to create groundbreaking medicines which do little more than staunch certain symptoms.</p><div class="paywall-selector"></div><div class="paywall">
<p>The FDA&#8217;s latest approval is for Endari, a drug created by the under-the-radar biotech Emmaus Medical Inc. As the agency itself notes, Endari is no cure. Rather, it&#8217;s approved to &#8220;reduce severe complications associated with the blood disorder,&#8221; such as extreme side effects in the lungs and major pain. The drug also cut down patients&#8217; needs to go to a hospital for sickle-cell related pain compared with placebo in clinical trials.</p>
<p style="text-align:center;"><a href="https://fortune.com/getbrainstormhealth/" target="_blank" rel="noopener noreferrer"><em>Click here</em></a> <em>to subscribe to Brainstorm Health Daily, our brand new newsletter about health innovations.</em></p>
<p>This is all welcome news for people who suffer from the genetic blood disorder, whose various forms afflict some 100,000 Americans at any given time, <a href="https://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk" target="_blank" rel="noopener noreferrer">according to the National Institutes of Health</a>. But there&#8217;s still a long way to go when it comes to combating a lifelong illness.</p>
<p>The slow pace of progress is common in these kinds of diseases—one which are degenerative and afflict just a sliver of the population. In recent years, the FDA has ramped up its efforts to approve drugs for rare diseases. That includes some controversial decisions to clear treatments that tackle a smattering of symptoms or are basically unproven from a clinical standpoint (consider the agency&#8217;s <a href="https://fortune.com/2017/02/10/muscular-dystrophy-drug-us/" target="_blank" rel="noopener noreferrer">recent approvals for Duchenne muscular dystrophy medicines</a> in the wake of patient group pressure).</p>
<p>The FDA has gone even further in some cases. Several months ago, regulators <a href="https://fortune.com/2017/05/08/fda-als-drug-approval/" target="_blank" rel="noopener noreferrer">approved the first new</a> amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, drug since 1995. In fact, the FDA actually asked the treatment&#8217;s manufacturer to submit it for U.S. regulatory approval following promising results in Japan. Once again, this new drug, while historic, is not a cure.</p>
<div class="vodvideocontainer" style="position: relative; padding-bottom: 56.25%;"><iframe src="//fortune.com/videos/embed/91a7b660-eac7-4f35-8481-ea9893647c7d" style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; overflow: hidden;" scrolling="no" frameborder="0" allowfullscreen></iframe></div>
<p>That may be of little concern to patients and their families desperate for any treatment avenue. But the high costs of these drugs, which are particularly hard to test and manufacture given the limited number of patients, raise potential ethical and financial concerns. Some insurance companies <a href="https://fortune.com/2016/12/14/insurers-rebel-sarepta-duchenne-drug/" target="_blank" rel="noopener noreferrer">have been reluctant</a> to cover therapies like the newly-approved Duchenne drugs because they may not produce results in line with their prices.</p>
<p>And if medicines which simply swat back some of a disease&#8217;s major symptoms, how much would an actual <em>cure </em>cost? At the moment, a number of companies—like Bluebird Bio—<a href="https://fortune.com/2017/03/03/sickle-cell-gene-therapy-cure/" target="_blank" rel="noopener noreferrer">are trying to create gene therapies</a> which may eliminate sickle cell disease. It may be unfair to put a price tag on good health. But it&#8217;s an issue that patients and the health care system at large will have to address as more novel medicines hit the market.</p></div>

The FDA has approved the first new sickle cell drug in decades, Emmaus' Endari. But, like other recent milestones, it's not a cure.

FDA Approved First New Sickle Cell Drug in 20 Years

legacy

Health

The FDA Approved the First New Sickle Cell Drug In 20 Years...But It's Not a Cure

FDA Approved First New Sickle Cell Drug in 20 Years | Fortune

Beth Greenfield

How much ultra-processed food is too much? The exact amount that raises your risk of heart disease and cancer

/well/2025/05/08/ultra-processed-food-amount-risk-heart-disease-cancer/

Ani Freedman

Men are more likely to get sick and less likely to seek care for 3 common diseases, study finds

/well/2025/05/07/men-health-hypertension-diabetes-hiv/

Teen girl using smartphone on her bed in the dark

The dangers of AI companions: Experts issue unprecedented warning for teens as most parents are in the dark about their habits

/well/2025/04/30/ai-companions-dangers-experts-issue-warning-for-teens/

Alexa Mikhail

Mark Zuckerberg reveals the morning routine that’s ‘better than caffeine’ 

/well/2025/04/29/mark-zuckerberg-morning-routine-caffeine/

Major food brands will stop using artificial dyes. Here’s why RFK is sounding the alarm

/well/2025/04/29/rfk-artificial-dyes-food-brands-will-stop-using/

These eating habit mistakes could lead to stress and burnout. 3 changes to make

/well/article/diet-mistakes-stress-burnout-vegan-ultra-processed-foods/

Chris Morris

Trump just declared May 8 a national holiday. What's open and closed?

https://fortune.com/article/open-closed-may-8-new-holiday-grocery-stores-retailers-restaurants-banks-wall-street/?itm_source=parsely-api

Marco Quiroz-Gutierrez

A group of anonymous traders scored a $100 million payday by buying Melania Trump's memecoin just before it launched publicly

https://fortune.com/2025/05/07/melania-trump-memecoin-anonymous-traders-100-million-payday/?itm_source=parsely-api

Sasha Rogelberg

Pandora CEO says producing jewelry in America 'simply won't work': 'I can't find that amount of talent that actually has this craft experience in the U.S.'

https://fortune.com/2025/05/07/pandora-ceo-alexander-lacik-thailand-tariffs-us-supply-chain-increased-prices/?itm_source=parsely-api

Greg McKenna

Defense contractor Palantir says a 'massive cultural shift in the U.S.' has justified 20 years of thankless toil. 'We were the freak show … and we spent 20 years for this moment'

https://fortune.com/2025/05/06/palantir-cultural-shift-us-justified-20-years-thankless-toil-freak-show/?itm_source=parsely-api

The hedge fund legend who predicted Black Monday sounds a new market warning, saying stocks will 'go down to new lows'

https://fortune.com/article/paul-tudor-jones-market-warning-tariffs/?itm_source=parsely-api

Alicia Adamczyk

Trump administration says 5.3 million student loan borrowers will have wages garnished this summer

https://fortune.com/article/trump-administration-student-loan-borrowers-wages-garnished-this-summer/?itm_source=parsely-api